• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Alerts
CMECNE

ISUOG Recommendations: Fetal Ultrasound Follow-Up for Women with Established Preeclampsia

image_pdfFavoriteLoadingFavorite

Learning Objectives and CME/Disclosure Information

This activity is intended for healthcare providers delivering care to women and their families.

After completing this activity, the participant should be better able to:

1. Recall the ISUOG recommendations for the role of ultrasound in the monitoring of patients who have a diagnosis of preeclampsia
2. Discuss the impact of common medications used to treat preeclampsia on Doppler indices

Estimated time to complete activity: 0.25 hours

Faculty:

Susan J. Gross, MD, FRCSC, FACOG, FACMG
President and CEO, The ObG Project

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty: Susan J. Gross, MD, receives consulting fees from Cradle Genomics, and has financial interest in The ObG Project, Inc.

Planners and Managers: The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.

Method of Participation and Request for Credit

Fees for participating and receiving CME credit for this activity are as posted on The ObG Project website. During the period from Dec 3 2018 through Dec 3 2021, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation. Upon registering and successfully completing the post-test with a score of 100% and the activity evaluation, your certificate will be made available immediately.

For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.2 contact hours.

Designated for 0.1 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Read Disclaimer & Fine Print

SUMMARY:

The ISUOG Clinical Standards Committee has released practice guidelines reviewing the latest evidence and provides recommendations regarding the role of ultrasound in follow-up for women diagnosed with preeclampsia.

KEY POINTS:

  • Close fetal surveillance is warranted as deteriorating fetal status may be an indication for earlier delivery
  • Sonographic follow up of PE should include
    • Fetal growth
    • Biophysical profile
    • Fetal Doppler assessments
  • Frequency and impact of sonographic follow up has yet to be determined by large-scale clinical trials

Role of B-mode Ultrasound

Ultrasound assessment should include

  • Fetal growth
    • Rule out impaired growth
  • Biophysical profile
    • BPP of >8: Normal – manifestation of fetal wellbeing
    • BPP of 6: Inconclusive – repeat test
    • BPP of ≤4: Non-reassuring – consider delivery
  • Amniotic fluid volume
    • Ensure presence of MVP >2 cm and/or AFI >5 cm
    • Evidence that MVP may result in fewer interventions (see ‘Related ObG Topics’ below)
  • Placentation
    • Thickness | Echogenicity | Uteroplacental interface
    • Severe PE may be associated with
      • Placental edema and diffuse echogenicity due to edema
      • Thick placenta and reduced vascularization
      • Cystic regions (infarctions/ hematomas)
    • Abruption (poor sensitivity with 50 to 75% missed on ultrasound
      • Hematoma (preplacental and retroperitoneal) | Subchorionic and marginal blood | Increased placental thickness and echogenicity

Role of Doppler Studies

  • 4 major Doppler exams
    • Umbilical artery (UA)
    • Fetal middle cerebral artery (MCA)
    • Fetal ductus venosus
    • Uterine arteries

Especially in the presence of maternal headache, abdominal pain, bleeding and/or reduced fetal movements consider

  • *UA
    • absent or reversed end-diastolic flow is strongly associated with poor perinatal outcomes
    • Increased resistance in the uterine arteries is not a useful indicator for timing of delivery
  • *Fetal MCA PI
    • Reduced MCA-PI <10th percentile (cephalization) may precede abnormal UA indices, and warrants close fetal surveillance
  • *Cerebroplacental ratio (CPR)
    • CPR: MCA PI / UA PI
    • CPR<10th percentile may represent hemodynamic redistribution
    • Warrants close fetal surveillance
  • Fetal ductus venosus
    • Unlike the above 3 indices (marked with *), ductus venosus is not included in ultrasound recommendation list (‘Good Practice Points’) for preeclampsia follow up
    • However, the guideline does point out that a reversed a-wave is strongly association with fetal cardiac deterioration

Note: ISUOG states that the above tests should also “be considered for women admitted for PE or with suspected PE, as well as for those with severe PE or HELLP syndrome” as a ‘Good Practice Point’.

Impact of Medications on Ultrasound Indices

  • Antihypertensives
    • Not associated with changes in maternal and fetal Doppler indices
  • Antenatal steroids
    • Associated with a transient decrease in vascular resistance in the UA and ductus venosus
  • Magnesium sulfate
    • Unclear

Learn More – Primary Sources:

ISUOG Practice Guidelines: role of ultrasound in screening for and follow up of pre-eclampsia

Take a post-test and get CME credits

TAKE THE POST TEST

image_pdfFavoriteLoadingFavorite

< Previous
All Alerts Posts
Next >

Related ObG Topics:

ISUOG Recommendations for Preeclampsia Prevention: Combined Screening and the Role of Ultrasound
Deepest Pocket or AFI When Performing Prenatal Ultrasound?  
Aspirin Treatment for Women at Risk for Preeclampsia – ACOG and USPSTF Recommendations  
ACOG Guidance: Emergency Treatment for Severe Hypertension in Pregnancy
ASPRE Trial: A Combined Risk Algorithm and Use of Aspirin to Prevent Preterm Preeclampsia
Diagnosing Preeclampsia – Key Definitions and ACOG Guidelines
ISUOG Recommendations: Fetal Ultrasound Follow-Up for Women with Established Preeclampsia

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site